Streetwise Expert Interviews

Richard Huebner

Investment Banker Dick Huebner on How to Uncover Micro-Cap Biotechs that Deliver on Promises

Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires extraordinary expertise and experience, and that is where micro-cap investment banker Richard "Dick" Huebner excels. In this interview with The Life Sciences Report, Huebner, a senior managing partner with Denver-based GVC Capital, discusses the downside and the upside of micro-cap biotech investment, and the desirable characteristics risk takers should be looking for in very small companies.

(11/20/14) More >
Read More Streetwise Interviews

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak

Steve Brozak's military background, combined with 20 years as a biotech and medtech analyst, has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. (11/13/14) More >

Ebola's Silver Lining: MLV & Co.'s George Zavoico

MLV & Co.'s George Zavoico brings a wealth of experience to bear on the valuations of smaller companies with phenomenal growth prospects, and discusses how the quest for a cure for Ebola could disrupt—and improve—our approach to medical crises. (11/12/14) More >

Newsletter Briefs

"MSLP has definitely proven itself a very capable marketing machine." (11/20/14) MusclePharm Corp. - The Life Sciences Report Interview with Dick Huebner More >

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers." (11/13/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"GLPG is notable and underappreciated." (11/12/14) Galapagos NV - The Life Sciences Report Interview with George Zavoico More >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17." (11/13/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"Positive data in the pancreatic or the sarcoma studies could take THLD shares to my target." (11/12/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

"We see a pretty healthy revenue stream coming from OMER's Omidria." (11/12/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >

"We find CTH to be a very compelling story." (10/30/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Brandon Primack More >

"We believe that OMER will become profitable in 2016." (11/6/14) Omeros Corp. - The Life Sciences Report Biotech Watchlist Update with George Zavoico More >

Expert Analysis

"Fourteen of 16 Parkinson's disease patients treated with CTH's APL-130277 were converted from 'off' to 'on'." (11/19/14) Cynapsus Therapeutics Inc. - Daniel Pearlstein, M Partners More >

"RXII is an undervalued player with significant upside long term." (11/18/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"We believe that the data set is our 'Good' scenario." (11/18/14) NeoStem Inc. - Jason Kolbert, Maxim Group More >

"STEM initiated a controlled Phase 2 trial in cervical SCI patients." (11/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"INO plans to continue development of INO-5150 (prostate cancer)." (11/17/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >

"Data from the Phase 1/3 GBM trial for THLD's TH-302 look positive." (11/17/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"RNN's clinical trial result reports might cluster in Q1/15." (11/13/14) Rexahn Pharmaceuticals Inc. - Yale Jen, Laidlaw & Company More >

"CGIX's Q3/14 revenue grew to $3.22M, representing 90% YOY growth." (11/10/14) Cancer Genetics Inc. - Thomas Pfister, RedChip Companies Inc. More >